A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract Meeting Abstract
| Authors: | Sarfaty, M.; Ostrovnaya, I.; Teo, M. Y.; Iyer, G.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; Al-Ahmadie, H.; Chaim, J.; Bajorin, D. F.; Rosenberg, J. E.; Funt, S. A. |
| Abstract Title: | A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract |
| Meeting Title: | 2020 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2020 Feb 13-15 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-02-20 |
| Language: | English |
| ACCESSION: | WOS:000529525900541 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.6_suppl.514 |
| Notes: | Meeting Abstract: 514 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
